Kapil Mayawala

Title: Innovations by Kapil Mayawala: A Focus on pH Dependent Antibodies

Introduction

Kapil Mayawala is an innovative inventor based in Peabody, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies with unique properties. His work focuses on enhancing the efficacy and longevity of therapeutic antibodies.

Latest Patents

Kapil Mayawala holds a patent for "Anti-PCSK9 antibodies with pH dependent antigen binding." This invention relates to antibodies that exhibit pH dependent binding to their antigen. The affinity for antigen binding at physiological pH (pH 7.4) is greater than at endosomal pH (pH 6.0 or 5.5). This characteristic allows the antibodies to preferentially dissociate from the antigen in the endosome, potentially increasing their half-life compared to traditional antibodies. The invention is particularly relevant for antigens that undergo antigen-mediated clearance, such as PCSK9.

Career Highlights

Throughout his career, Kapil Mayawala has worked with notable companies in the biotechnology sector. He has been associated with Rinat Neuroscience Corporation and Pfizer Corporation, where he contributed to various innovative projects. His experience in these organizations has helped him refine his skills and knowledge in the field of antibody development.

Collaborations

Kapil has collaborated with esteemed colleagues, including Jaume Pons and Jeffrey Raymond Chabot. These collaborations have further enriched his research and development efforts in the biotechnology domain.

Conclusion

Kapil Mayawala's work on pH dependent antibodies represents a significant advancement in therapeutic antibody design. His innovative approach has the potential to improve treatment outcomes for various medical conditions.